AnaptysBio Stock
AnaptysBio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Daniel Faga
- Employees
- 104
- Market cap
- $1.4 B
- IPO
- 26/01/2017
AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, United States. The company focuses on delivering immunology therapeutics for the treatment of autoimmune and inflammatory diseases. Its product pipeline includes several antibody programs that have advanced to preclinical and clinical…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
AnaptysBio stock: price history
1D
-4.3%
1W
+1.4%
1M
-14.2%
6M
+3.6%
YTD
+44.2%
1Y
+103.3%
2Y
+101.5%
5Y
+143.9%
10Y
–
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~16% weaker price swings than usual
Ask the agents about AnaptysBio
Analyst assessment of AnaptysBio
PRICE TARGET LOW
US$70.00
CONSENSUS
US$79.17
MEDIAN
US$77.00
PRICE TARGET HIGH
US$95.00
0
STRONG BUY
17
BUY
6
HOLD
0
SELL
0
STRONG SELL
23
TOTAL · Buy
As of: 30/09/2026
AnaptysBio stock metrics
P/E
6.91
P/B
128.86
EV/EBITDA
16.64
RETURN ON EQUITY
1,737.2%
NET MARGIN
668.9%
DEBT/EQUITY
25.47
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.4%
FLOAT SHARES
27,916,138
AVG. DAILY VOLUME (30D)
568,786
Insider transactions (SEC)
RENTON HOLLINGS
RENTON HOLLINGS
Orwin John A
RENTON HOLLINGS
Orwin John A
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.3%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about AnaptysBio stock
What does AnaptysBio do?
AnaptysBio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Daniel Faga, the company employs around 104 people.
The IPO was on 26/01/2017; the stock trades on NASDAQ under the ticker ANAB.
What do analysts say about AnaptysBio stock?
23 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$79.17, ranging from US$70.00 to US$95.00, with a median of US$77.00.
This is an external assessment, not a statement by Market Jury.
When does AnaptysBio report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -16% stronger than usual.
Does AnaptysBio pay a dividend?
No, AnaptysBio currently does not pay a dividend.
Which stocks are comparable to AnaptysBio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get AnaptysBio stock analyzed?
Clicking "Analyze stock" lets five strategies assess AnaptysBio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.